BioAtla, Inc. (BCAB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BCAB currently has 1.5M outstanding shares. with limited dilution risk as only 194K additional shares (12.9%) are authorized for issuance. The company has significantly diluted shareholders by 62.92% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 1.5M shares outstanding |
1.5M | 190K |
| Apr 06, 2026 |
Stock Split
8-K filing: Stock split 1-for-50 | Outstanding: 82,846,317 → 1,656,926 |
1.7M | 190K |
| Mar 31, 2026 |
10-K filing | 82.8M shares outstanding |
83M | 9.7M |
| Jan 16, 2026 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $200,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities. |
59M | 9.7M |
| Nov 21, 2025 |
8-K filing: BioAtla, Inc. entered into a Pre-Paid Advance Agreement with investors for a $7.5 million advance and a Standby Equity Purchase Agreement with Yorkville for the right to sell up to $15.0 million of common stock. |
59M | 9.7M |
| Aug 07, 2025 |
10-Q filing | 58.5M shares outstanding |
59M | 9.7M |
| May 06, 2025 |
10-Q filing | 58.2M shares outstanding |
58M | 9.7M |
| May 06, 2025 |
S-3 filing: This prospectus relates to the resale from time to time, by the selling securityholders of up to 9,679,158 shares of our common stock that they may acquire upon the exercise of outstanding warrants. |
58M | 9.7M |
| Mar 28, 2025 |
10-K filing | 58.4M shares outstanding |
58M | 0 |
| Nov 07, 2024 |
10-Q filing | 48.3M shares outstanding |
48M | 0 |
| Aug 08, 2024 |
10-Q filing | 48.2M shares outstanding |
48M | 0 |
| May 14, 2024 |
10-Q filing | 48.1M shares outstanding |
48M | 0 |
| Mar 26, 2024 |
10-K filing | 47.8M shares outstanding |
48M | 0 |
| Nov 07, 2023 |
10-Q filing | 47.8M shares outstanding |
48M | 0 |
| Aug 01, 2023 |
10-Q filing | 47.7M shares outstanding |
48M | 0 |
| May 11, 2023 |
10-Q filing | 47.6M shares outstanding |
48M | 0 |
| Mar 23, 2023 |
10-K filing | 47.6M shares outstanding |
48M | 0 |
| Jan 06, 2023 |
S-3 filing: The filing is an S-3 form for a shelf offering of common stock, preferred stock, and debt securities, with a total proposed amount of $200,000,000. |
38M | 0 |
| Nov 04, 2022 |
10-Q filing | 37.5M shares outstanding |
38M | 0 |
| Aug 09, 2022 |
10-Q filing | 37.4M shares outstanding |
37M | 0 |
| May 17, 2022 |
POS AM filing: This is a POS AM filing that includes exhibits related to the company's securities offerings, including underwriting agreements, forms of stock certificates, and agreements related to preferred stock and warrants. |
36M | 0 |
| May 05, 2022 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| Mar 01, 2022 |
POS AM filing: The company may offer and sell up to $200,000,000 in the aggregate of any combination of common stock, preferred stock, debt securities, warrants and units. |
36M | 0 |
| Feb 28, 2022 |
10-K filing | 35.8M shares outstanding |
36M | 0 |
| Nov 15, 2021 |
10-Q filing | 35.3M shares outstanding |
35M | 0 |
| Oct 22, 2021 |
S-1 filing: This S-1 filing relates to the potential sale of common stock by selling stockholders. The company will not receive any proceeds from this offering. |
32M | 0 |
| Sep 29, 2021 |
8-K filing: BioAtla, Inc. entered into Stock Purchase Agreements to issue and sell 2,678,600 shares of its common stock at $28.00 per share to accredited investors for gross proceeds of $75.0 million, with the closing expected on or about September 30, 2021. ($75.0M proceeds) |
32M | 0 |
| Aug 13, 2021 |
10-Q filing | 32.3M shares outstanding |
32M | 0 |
| May 12, 2021 |
10-Q filing | 32.2M shares outstanding |
32M | 0 |
| Nov 13, 2020 |
S-1 filing: S-1 filing for an initial public offering of common stock. |
280M | 0 |